Viomics provides molecular diagnostic services for the early detection of lung cancer through non-invasive blood draws and targeted RNA screening. Their services enable real-time monitoring of tumor events and the identification of specific markers in the blood, allowing doctors and patients to access targeted therapy and early detection. With extensive sequencing capabilities and expertise in identifying unique biomarkers, Viomics is able to detect the presence of cancer in solid tissue and blood.